Pulse Biosciences Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
PLSE$55.12-5.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities: | ||
| Net loss | $(42,210) | $(58,505) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 542 | 690 |
| Amortization of intangible assets | 665 | 665 |
| Stock-based compensation | 7,181 | 5,191 |
| Write-off of excessive and obsolete inventory | — | 8,477 |
| Loss on disposal of fixed assets | 13 | 185 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | — | 61 |
| Inventory | — | (2,653) |
| Prepaid expenses and other current assets | (65) | 1,164 |
| Other receivables | 109 | (41) |
| Right-of-use assets | 806 | 723 |
| Accounts payable | 263 | (1,304) |
| Accrued expenses | 1,219 | (1,794) |
| Deferred revenue | — | (16) |
| Lease liabilities | (896) | (774) |
| Accrued interest on related party note payable | (668) | 917 |
| Accrued interest on note payable | — | 1 |
| Net cash used in operating activities | (33,041) | (47,013) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (121) | (401) |
| Net cash used in investing activities | (121) | (401) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock under employee stock purchase plan | 395 | 486 |
| Proceeds from exercises of warrants | 14,828 | 26 |
| Proceeds from exercises of stock options | 1,171 | — |
| Proceeds from issuance of common stock | — | 14,864 |
| Proceeds from issuance of related party note | — | 65,000 |
| Issuance cost in relation to related party note extinguishment | (6) | — |
| Payments made on insurance loan agreement | — | (437) |
| Net cash provided by financing activities | 16,388 | 79,939 |
| Net (decrease) increase in cash and cash equivalents | (16,774) | 32,525 |
| Cash and cash equivalents at beginning of period | 61,139 | 28,614 |
| Cash and cash equivalents at end of period | $44,365 | $61,139 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Principal and accrued interest of related party note settled via issuance of common stock | $(65,249) | $— |
| Equipment purchases included in accounts payable and accrued expenses | $— | $(27) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.